Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2014, Vol. 34 Issue (3): 84-90    DOI: 10.13523/j.cb.20140312
    
Experimental Screening mRNA Targets by Reverse Transcription for Ribozyme to GPA Expression Interference
FU Hui1,2, LI Fei-fei2, MA Qiong2, FU Huai-xiu2, CUI Yu-fang2, MAO Jian-ping2
1. Medical University of Anhui, Hefei 230032, China;
2. Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China
Download: HTML   PDF(1473KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

An oligodeoxynucleotide library which the sequence were defined at 5 prime and randomized at 3 prime was employed to screen mRNA accessible targets, in reverse transcription and PCR after hybridized the library with mRNA. The mRNA of Glycophorin A(GPA), type I transmembrane glycoprotein, was screened and obtained 4 targets sequences. Accordingly 4 antisense nucleic acids designed respectively, the binding efficiency of every target were verified by using RNase H with antisense nucleic acids. Among them 2 targets showed better effects on binding and cutting. Designed 2 ribozymes to these targets, packaged in lentivirus system, then infected K562 cells(human erythroid leukemia line), the down-regulation effect of gene expression was validated by Real Time RT-PCR and by Western Blot. It was found that the screened targets showed the best effective knocking down effects on gene expression. The study provided a reference for mRNA targets screening and Ribozyme design, and was helpful in membrane receptor expression interference, since GPA is a transmembrane protein.



Key wordsGlycophorin A      mRNA      Target      Ribozyme      Lentivirus      K562     
Received: 21 January 2014      Published: 25 March 2014
ZTFLH:  Q522  
  Q752  
  R914.2  
Cite this article:

FU Hui, LI Fei-fei, MA Qiong, FU Huai-xiu, CUI Yu-fang, MAO Jian-ping. Experimental Screening mRNA Targets by Reverse Transcription for Ribozyme to GPA Expression Interference. China Biotechnology, 2014, 34(3): 84-90.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20140312     OR     https://manu60.magtech.com.cn/biotech/Y2014/V34/I3/84

[1] 周颖, 毛建平. Ribozyme和DNAzyme的基因治疗实验应用进展. 中国生物工程杂志, 2010, 30(6): 122-129. Zhou Y, Mao J P. Pre-clinical application and perspective of ribozyme and DNAzyme. Chin Biotechnology, 2010, 30(6): 122-129.
[2] Rayburn E R, Zhang R W. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today, 2008, 13(11-12): 513-521.
[3] 吴启家, 黄林, 张翼. 催化RNA的结构与功能. 中国科学C辑: 生命科学, 2009, 39(1): 78-90. Wu Q J, Huang L, Zhang Y. Science in China Press, 2009, 39(1): 78-90.
[4] 王全会, 毛建平. mRNA靶点筛选方法研究进展. 中国生物工程杂志, 2003, 23(3):1-5. Wang Q H, Mao J P. Progress of RNA target sites screening. Chin Biotechnology, 2003, 23(3):1-5.
[5] Southern E M, Case Green S C, Elder S C, et al. Arrays of complimentary oligonucleotides for analyzing the hybridization behaviour of nucleic acids. Nucleic Acids Res, 1994, 22, 1368-1373.
[6] Milner N, Mir K U, Southern E M. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotechnol, 1997, 15, 537-541.
[7] Pan Wei hua, Heidi F D, Colleen K, et al.A selection system for identifying accessible sites in target RNAs.RNA, 2001, (7): 610-621
[8] Hatim T, Fang Dong, Hon S I, et al. Mapping of RNA accessible sites by extension of random oligonucleotide libraries with reverse transcriptase.RNA. 2001, (7):314-327
[9] Ilka B, Annette G B. Illuminating the life of GPCRs. Cell Commun Signal, 2009;7:16-19.
[10] 毛建平, 王全会, 施水兰, 等. 绿色荧光蛋白基因mRNA反义寡核苷酸的筛选和应用. 中国生物化学与分子生物学报, 2005, 21(49):529-536. Mao J P, Wang Q H, Shi SH L, et al. Application of antisense oligonucleotides designed to screened green fluorescence protein mRNA accessible sites. Chin J Biochem Mol Biol, 2005, 21(49):529-536.
[11] 毛建平, 毛秉智. 基因药物研究现状和对策. 中国生物化学与分子生物学报, 2004, 20(2): 143-148. Mao J P, Mao B ZH. Advannces and strategies in gene drugs development. Chin J Biochem Mol Biol, 2004, 20(2): 143-148.
[12] Podbielska M, Krotkiewski H.Identification of blood group A and B antigens in human glycophorin. Arch Immunol Ther Exp, 2000, 48(3):211-218.

[1] WANG Yu-xuan,CHEN Ting,ZHANG Yong-liang. Research Progress on the Biological Function of MiR-148[J]. China Biotechnology, 2021, 41(7): 74-80.
[2] LIU Shao-jin,FENG Xue-jiao,WANG Jun-shu,XIAO Zheng-qiang,CHENG Ping-sheng. Market Analysis and Countermeasures of Nucleic Acid Drugs in China[J]. China Biotechnology, 2021, 41(7): 99-109.
[3] CHEN Wen-jie,MIAO Xian-feng. Domestic Research and Development Status of Antibody-drug Conjugates and Strategic Layout of Key Enterprises[J]. China Biotechnology, 2021, 41(6): 105-110.
[4] BI Bo,ZHANG Yu,ZHAO Hui. Application of Yeast Hybrid System in Study of Off-target Rate of CRISPR/Cas9 Gene Editing System[J]. China Biotechnology, 2021, 41(6): 27-37.
[5] TAO Shou-song,REN Guang-ming,YIN Rong-hua,YANG Xiao-ming,MA Wen-bing,GE Zhi-qiang. Knockdown of Deubiquitinase USP13 Inhibits the Proliferation of K562 Cells[J]. China Biotechnology, 2021, 41(5): 1-7.
[6] LV Hui-zhong,ZHAO Chen-chen,ZHU Lian,XU Na. Progress of Using Exosome for Drug Targeted Delivery in Tumor Therapy[J]. China Biotechnology, 2021, 41(5): 79-86.
[7] HU Sheng-tao,ZHANG Er-bing,LIN Ye,ZHANG Feng,HUANG Dan,SONG Hou-pan,LIU Bin,CAI Xiong. Research Advances on the Therapy of Rheumatoid Arthritis with the Nanotechnology Based on Transdermal Drug Delivery System[J]. China Biotechnology, 2021, 41(2/3): 98-106.
[8] YANG Ruo-nan,XU Li,XU Ping,SU Yan. The Development Situation and Suggestions of RNA Therapy Industry[J]. China Biotechnology, 2021, 41(2/3): 162-171.
[9] TANG Yue-wei,LIU Zhi-ping. Drug-target Affinity Prediction Based on Deep Learning and Multi-layered Information Fusion[J]. China Biotechnology, 2021, 41(11): 40-47.
[10] WU You,XIN Lin. New Drug Delivery System: Delivery of Exosomes as Drug Carriers[J]. China Biotechnology, 2020, 40(9): 28-35.
[11] JIANG Dan-dan,WANG Yun-long,LI Yu-lin,Zhang Yi-qing. Study on the Delivery of RGD Modified Virus-Like Particles to ICG Targeted Tumors[J]. China Biotechnology, 2020, 40(7): 22-29.
[12] HUANG Sheng, YAN Qi-tao, XIONG Shi-lin, PENG Yi-qi, ZHAO Rui. Construction of CHD5 Gene Overexpressing Lentiviral Vector Based on CRISPR/Cas9-SAM System and the Effect of CHD5 on Proliferation, Migration and Invasion in T24 Cells[J]. China Biotechnology, 2020, 40(3): 1-8.
[13] CAO Meng,ZHAO Yu-hao,GUO Zhong-ping. A Review of the Global Bio-Therapeutics Development Process from the Perspective of International Nonproprietary Names[J]. China Biotechnology, 2020, 40(1-2): 154-165.
[14] JING Hui-yuan,DUAN Er-zhen,DONG Wang. In Vitro Transcribed Self-amplifying mRNA Vaccines[J]. China Biotechnology, 2020, 40(12): 25-30.
[15] XIAO Xue-jun,TANG Qi,XINHUA Nabi. CAR-T Therapy Targeting Tumor Microenvironment[J]. China Biotechnology, 2020, 40(12): 67-74.